SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Madrigal Pharmaceuticals
MDGL 407.16-2.8%9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (112)7/19/2019 1:03:30 PM
From: tuck  Read Replies (2) of 138
 
I'm a little concerned about the powering for the stage 2/3 cohorts now. To my knowledge they haven't broken out outcomes for the stage 1 patients in the P2 study, even though it was close to half the study population. Apparently the inclusion of high risk stage 1 ("stage1B" was at least slipped into their corporate presentation from last month, but the nuance I'm pointing at escaped my attention until today when I noticed the changes the trial protocol at clinicaltrials.gov. I suppose I should have been concerned about the absence of stage 1 patients in the P3 protocol until now, as they did say they intended to replicate the P2 study wrt patient population. Just wish we could see the data, because if it's really replicating the P2, but with higher doses, the stage 1 cohort will be very large. Anyway, thoughts?

Last Q, they vaguely said that enrollment was going well. Still just the Pinnacle sites. If they want to speed enrollment, HOW ABOUT OPENING SOME SITES IN OTHER STATES? They don't have conference calls for earnings, so no one gets to ask them about this stuff. Nothing new in the poster for the Paris NASH meeting.

Getting a little frustrated with the transparency wrt to stage 1 data considering the above.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News